MARKET

ADCT

ADCT

Adc Therapeutics Sa
NYSE

Real-time Quotes | Nasdaq Last Sale

7.97
-0.08
-0.99%
Closed 17:06 08/09 EDT
OPEN
7.87
PREV CLOSE
8.05
HIGH
8.08
LOW
7.64
VOLUME
219.58K
TURNOVER
--
52 WEEK HIGH
32.00
52 WEEK LOW
5.52
MARKET CAP
612.18M
P/E (TTM)
-3.1343
1D
5D
1M
3M
1Y
5Y
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 23.96% and 14.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 23h ago
ADC Therapeutics: Q2 Earnings Insights
  ADC Therapeutics (NYSE:ADCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 23h ago
ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
ADC Therapeutics press release (<span class="...
Seekingalpha · 1d ago
ADC Therapeutics Q2 EPS $(0.73) Beats $(0.91) Estimate
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the
Benzinga · 1d ago
ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
LAUSANNE, Switzerland, August 09, 2022--ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
Business Wire · 1d ago
Earnings Outlook For ADC Therapeutics
  ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ADC Therapeutics will report an earnings per share (EPS) of $-0.91...
Benzinga · 1d ago
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and +5.86%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Misses Revenue Estimates
Intercept (ICPT) delivered earnings and revenue surprises of -28.30% and 24.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6d ago
More
No Data
Learn about the latest financial forecast of ADCT. Analyze the recent business situations of Adc Therapeutics Sa through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

42.86%Strong Buy
57.14%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADCT stock price target is 27.17 with a high estimate of 44.00 and a low estimate of 15.00.
High44.00
Average27.17
Low15.00
Current 7.97
EPS
Actual
Estimate
-0.74-0.56-0.37-0.19
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 56
Institutional Holdings: 35.19M
% Owned: 45.81%
Shares Outstanding: 76.81M
TypeInstitutionsShares
Increased
17
705.11K
New
3
406.09K
Decreased
11
524.11K
Sold Out
10
326.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.83%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman
Ron Squarer
Chief Executive Officer/Executive Director
Christopher Martin
Vice Chairman/Executive Vice President/General Counsel/Director
Michael Forer
Chief Financial Officer
Jennifer Creel
Chief Human Resource Officer/Senior Vice President
Kimberly Pope
Senior Vice President
Joseph Camardo
Senior Vice President
Jennifer Herron
Senior Vice President
Patrick Van Berkel
Chief Accounting Officer/Vice President/Controller
Robert Schmidt
Chief Compliance Officer
Susan Romanus
Vice President
Lisa Skelton
Vice President - Business Development
Richard Onyett
Other
Peter Greaney
Non-Executive Independent Director
Peter Corr
Non-Executive Independent Director
Stephen Evans-freke
Non-Executive Independent Director
Peter Hug
Non-Executive Independent Director
Viviane Monges
Non-Executive Independent Director
Thomas Pfisterer
Non-Executive Independent Director
Thomas Rinderknecht
Non-Executive Independent Director
Tyrell Rivers
Non-Executive Independent Director
Victor Sandor
Non-Executive Independent Director
Jacques Theurillat
No Data
No Data
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

Webull offers kinds of ADC Therapeutics SA stock information, including NYSE:ADCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADCT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADCT stock methods without spending real money on the virtual paper trading platform.